310 related articles for article (PubMed ID: 26585874)
1. Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies.
Tran T; Brophy JM; Suissa S; Renoux C
CNS Drugs; 2015 Dec; 29(12):985-98. PubMed ID: 26585874
[TBL] [Abstract][Full Text] [Related]
2. Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review.
Steiger M; Jost W; Grandas F; Van Camp G
J Neural Transm (Vienna); 2009 Feb; 116(2):179-91. PubMed ID: 19142570
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.
Simonis G; Fuhrmann JT; Strasser RH
Mov Disord; 2007 Oct; 22(13):1936-42. PubMed ID: 17659636
[TBL] [Abstract][Full Text] [Related]
4. Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study.
Trifirò G; Mokhles MM; Dieleman JP; van Soest EM; Verhamme K; Mazzaglia G; Herings R; de Luise C; Ross D; Brusselle G; Colao A; Haverkamp W; Schade R; van Camp G; Zanettini R; Sturkenboom MC
Drug Saf; 2012 Feb; 35(2):159-71. PubMed ID: 22204718
[TBL] [Abstract][Full Text] [Related]
5. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
Antonini A; Poewe W
Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
[TBL] [Abstract][Full Text] [Related]
6. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
N Engl J Med; 2007 Jan; 356(1):39-46. PubMed ID: 17202454
[TBL] [Abstract][Full Text] [Related]
7. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
Junghanns S; Fuhrmann JT; Simonis G; Oelwein C; Koch R; Strasser RH; Reichmann H; Storch A
Mov Disord; 2007 Jan; 22(2):234-8. PubMed ID: 17094087
[TBL] [Abstract][Full Text] [Related]
8. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
Kvernmo T; Härtter S; Burger E
Clin Ther; 2006 Aug; 28(8):1065-1078. PubMed ID: 16982285
[TBL] [Abstract][Full Text] [Related]
9. Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.
De Vecchis R; Esposito C; Ariano C
Herz; 2013 Dec; 38(8):868-80. PubMed ID: 23743769
[TBL] [Abstract][Full Text] [Related]
10. Heart abnormalities in Parkinson patients after discontinuation or continuation of ergot-derived dopamine agonists: a treatment-blinded echocardiographic study.
Rasmussen VG; Poulsen SH; Dupont E; Østergaard K; Safikhany G; Egeblad H
J Heart Valve Dis; 2009 Jul; 18(4):463-9. PubMed ID: 19852154
[TBL] [Abstract][Full Text] [Related]
11. Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's disease.
Montastruc F; Moulis F; Araujo M; Chebane L; Rascol O; Montastruc JL
Eur J Clin Pharmacol; 2017 Jan; 73(1):99-103. PubMed ID: 27796464
[TBL] [Abstract][Full Text] [Related]
12. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
Cardiovasc Ther; 2011 Dec; 29(6):404-10. PubMed ID: 20553285
[TBL] [Abstract][Full Text] [Related]
13. Dopamine agonists and the risk of cardiac-valve regurgitation.
Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E
N Engl J Med; 2007 Jan; 356(1):29-38. PubMed ID: 17202453
[TBL] [Abstract][Full Text] [Related]
14. The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease.
Mokhles MM; Trifirò G; Dieleman JP; Haag MD; van Soest EM; Verhamme KM; Mazzaglia G; Herings R; Luise Cd; Ross D; Brusselle G; Colao A; Haverkamp W; Schade R; Camp Gv; Zanettini R; Sturkenboom MC
Pharmacol Res; 2012 Mar; 65(3):358-64. PubMed ID: 22123498
[TBL] [Abstract][Full Text] [Related]
15. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
[TBL] [Abstract][Full Text] [Related]
16. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
Kim JY; Chung EJ; Park SW; Lee WY
Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692
[TBL] [Abstract][Full Text] [Related]
17. Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease.
Rasmussen VG; Poulsen SH; Dupont E; Østergaard K; Safikhany G; Egeblad H
J Intern Med; 2008 Jan; 263(1):90-8. PubMed ID: 18036161
[TBL] [Abstract][Full Text] [Related]
18. High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.
Oeda T; Masaki M; Yamamoto K; Mizuta E; Kitagawa N; Isono T; Taniguchi S; Doi K; Yaku H; Yutani C; Kawamura T; Kuno S; Sawada H
J Neural Transm (Vienna); 2009 Feb; 116(2):171-8. PubMed ID: 19082526
[TBL] [Abstract][Full Text] [Related]
19. Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study.
Peralta C; Wolf E; Alber H; Seppi K; Müller S; Bösch S; Wenning GK; Pachinger O; Poewe W
Mov Disord; 2006 Aug; 21(8):1109-13. PubMed ID: 16622856
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
Van Camp G; Flamez A; Cosyns B; Weytjens C; Muyldermans L; Van Zandijcke M; De Sutter J; Santens P; Decoodt P; Moerman C; Schoors D
Lancet; 2004 Apr; 363(9416):1179-83. PubMed ID: 15081648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
